Skip to main content
. Author manuscript; available in PMC: 2016 Jan 21.
Published in final edited form as: Oncogene. 2014 Sep 8;34(27):3536–3546. doi: 10.1038/onc.2014.281

Figure 7.

Figure 7

Sensitivity of vGPCR-expressing cells to YAP inhibition. (a) Stable SVEC cells expressing vGPCR or BRAFV600E were established, and YAP/TAZ protein levels were assessed. (b) Verteporfin inhibits survival of cells expressing vGPCR. SVEC cells expressing vGPCR or BRAFV600E were seeded at same density, and treated with different doses of verteporfin for 72 hrs, cell numbers are then counted. (c, d) Verteporfin inhibits anchorage-dependent growth of cells expressing vGPCR. SVEC cells expressing vGPCR or BRAFV600E were seeded into soft agar at 3 X 104 cells/well. selected groups of cells were treated with 0.3 μM Verteporfin. After twenty days, colonies were visualized with crystal violet staining and quantified.